Pure Global
NCT06090136

Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects

A Study Evaluating Safety and Pharmacokinetics of a Single Oral TPN171H in Elderly Subjects
Vigonvita Life Sciences·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Erectile Dysfunction
Drug/Device/Intervention
TPN171H
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vigonvita Life Sciences
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Sep 14, 2020
End date
Jul 22, 2022
Enrollment
12 participants
Primary outcome

Adverse events,Pharmacokinetic parameter of TPN171H:Tmax,Pharmacokinetic parameter of TPN171H:Cmax,Pharmacokinetic parameter of TPN171H:T1/2,Pharmacokinetic parameter of TPN171H:AUC0-t,Pharmacokinetic parameter of TPN171H:AUC0-∞,Pharmacokinetic parameter of TPN171H:AUC0-24h,Pharmacokinetic parameter of TPN171H:Ke,Pharmacokinetic parameter of TPN171H:Vd,Pharmacokinetic parameter of TPN171H:MRT,Pharmacokinetic parameter of TPN171H:CL/F,Pharmacokinetic parameter of TPN171H:BRPP

Summary

It is a single-center, open-label, Phase I clinical study evaluating the safety and
 pharmacokinetics of a single oral TPN171H in elderly subjects.

ICD-10 classifications
Orgasmic dysfunctionOther disorders of penisOther specified disorders of penisSexual dysfunction, not caused by organic disorder or diseaseTesticular dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06090136
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06090136 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Completed. The study focuses on Erectile Dysfunction. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.